Amidoxime functionalized mesoporous silica nanoparticles for pH-responsive delivery of anticancer drug

Abstract In recent decades, nanomedicine has attracted much attention at the forefront of nanotechnology, gaining great expectations in the biomedical sectors. Among various nanomaterials, silica nanoparticles-based drug delivery is considered effective owing to their physicochemical stability and b...

Full description

Saved in:
Bibliographic Details
Published inZeitschrift für physikalische Chemie (Neue Folge)
Main Authors Santhamoorthy, Madhappan, Suresh, Ranganathan, Ramkumar, Vanaraj, Guganathan, Loganathan, Thirupathi, Kokila, Periyasami, Govindasami, Mohan, Anandhu, Kim, Seong-Cheol
Format Journal Article
LanguageEnglish
Published 12.03.2024
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract In recent decades, nanomedicine has attracted much attention at the forefront of nanotechnology, gaining great expectations in the biomedical sectors. Among various nanomaterials, silica nanoparticles-based drug delivery is considered effective owing to their physicochemical stability and biological compatibility. Surface grafting and chemical conversion techniques were used to create an amphoteric functional ligand known as amidoxime ligand (AL) modified mesoporous silica material (MS-AL NPs). With this technique, amidoxime ligand groups can be introduced in greater concentration to the silica surface without compromising its structure. The active surface allows for surface functionalization and integration of medicinal substances. They are widely employed in the bio-medical industry for diagnostics, target administration of drugs, bio-sensing, cellular absorption, and so on. The function of the produced MS-AL NPs as a regulated drug delivery system was studied utilizing doxorubicin (Dox) as a model anticancer drug. Using the MCF-7 cell line, the biocompatibility and cellular uptake characteristics were investigated. Considering all factors, the MS-AL NPs may be used as pH-responsive drug carriers in cancer treatment applications.
ISSN:0942-9352
2196-7156
DOI:10.1515/zpch-2023-0488